STAT+: Why biotech’s future is threatened by zombies
The state of the biotech investing is dark. Here's one reason why.
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
I was a bit worried last week’s angst-y rant on the bleak state of biotech investing would turn folks off. In fact, it was my most popular newsletter ever, with the version posted to STAT’s website delivering a ton of new subscribers. Thank you!
Why did “Biotech is in a dark place” resonate with so many of you? Because it’s true! Collectively, we’re all frustrated after running in place for five-plus years, and by recognizing the problem, hopefully, some cages are rattled and positive change happens.
